NLS Pharmaceutics (NLSP) said Tuesday its preclinical investigation provides evidence that Mazindol may offer a novel, non-opioid approach for the treatment of fentanyl use disorder.

The study, which assessed the rewarding effects of fentanyl and the impact of Mazindol in mice, showed that Mazindol significantly reduced fentanyl-induced conditioned place preference, the company said.

Shares of NLS Pharmaceutics were up nearly 3% in recent trading.

Price: 1.49, Change: +0.04, Percent Change: +2.90